Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tofacitinib citrate to medicine for adjuvant treatment of senile degenerative valvular disease

A technology of tofacitinib and adjuvant therapy, which is applied in the field of application of tofacitinib citrate in the adjuvant treatment of senile degenerative heart valve disease, and can solve the problems of poor long-term effect and low surgical risk

Active Publication Date: 2017-06-30
JIANGSU WANBANG BIOPHARMLS
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently used clinically, percutaneous aortic balloon valvuloplasty, which replaces aortic valve replacement, has low cost and low surgical risk, but its long-term effect is poor. Therefore, there is an urgent need for a drug for the treatment of SDHVD. effective treatment of symptomatic patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1 Adjuvant therapeutic effect of tofacitinib citrate on elderly patients with degenerative heart valve disease

[0012] 1. Materials and methods

[0013] 1.1 Experimental objects and grouping

[0014] 69 cases of SDHVD patients (diagnostic criteria: thickening of aortic valve and mitral valve or valve ring, calcification, enhanced reflection, regular edge, decreased activity; X-ray examination found that the aortic valve or mitral valve had calcification ; A systolic murmur above grade two or a diastolic murmur was heard in the aortic valve area, or murmurs were heard in both the aortic valve area and the mitral valve area.) Randomly divided into observation group 39 cases and control group 30 cases, two There was no significant difference in the gender and condition of the two groups after statistical processing ( p >0.05), it is comparable.

[0015] 1.2 Treatment methods

[0016] Patients in the observation group and the control group were actively treated...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel application of a medicine, and in particular relates to an adjuvant treatment effect of tofacitinib on senile degenerative valvular disease. A clinical trial research shows that while conventional treatment is carried out on a patient with the senile degenerative valvular disease, the tofacitinib can be given for adjuvant treatment; the tofacitinib can be used for remarkably treating lung extravasated blood and pleural effusion symptoms of the patient with the senile degenerative valvular disease; various arrhythmia including auricular fibrillation and the like, atrial hypertrophy and ventricular hypertrophy are effectively relieved; the recurrence rate of the disease can be reduced, and the life quality of the patient is improved.

Description

technical field [0001] The present invention relates to a new application of medicine, in particular to the application of tofacitinib citrate in adjuvant treatment medicine for senile degenerative heart valve disease. Background technique [0002] Senile degenerative heart valvular disease (SDHVD) is also known as senile calcific heart valve disease and senile heart calcification syndrome. The disease refers to the degeneration, fibrosis, thickening and calcification of the connective tissue of the heart valve on the basis of the original normal valve or mild valve abnormality, which causes the function of the valve and the stent. Abnormalities, mainly invading the aortic valve and mitral valve ring, mainly including calcified aortic valve stenosis and regurgitation, mitral valve ring and mitral valve calcification, and combined valve calcification with two valves at the same time, etc. In severe cases, it causes hemodynamic changes, which has become one of the main causes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/519A61P9/00A61P9/04
CPCA61K31/519
Inventor 王伟高雪芹李惠珠乔德水
Owner JIANGSU WANBANG BIOPHARMLS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com